aspirin has been researched along with carfilzomib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Derkach, A; Hassoun, H; Hultcrantz, M; Korde, N; Lesokhin, A; Lu, S; Mailankody, S; Orozco, J; Patel, D; Peterson, T; Piedra, K; Shah, U; Tan, C; Wilkins, CR | 1 |
2 other study(ies) available for aspirin and carfilzomib
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bortezomib; Dexamethasone; Disease Management; Disease Susceptibility; Female; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Staging; Oligopeptides; Retrospective Studies; Venous Thromboembolism | 2022 |